Alzheimer's Disease and Dementia
An Introduction to Alzheimer's Disease and Dementia
Major advances in the understanding of the pathogenesis of Alzheimer’s disease (AD), the most common form of dementia, have occurred over recent years, but the need for truly disease-modifying therapies remains. Novel pharmacotherapy strategies under investigation include the repurposing of medications used to treat non-AD illnesses and multi-target-directed ligands, offering promise in this challenging treatment landscape.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from our journal touchREVIEWS in Neurology. This is complimented by a range of educational activities developed in collaboration with our leading expert faculty.
Our supporting partners do not constitute an endorsement of the content on this page.
Leading experts share their perspectives on the most important therapeutic and treatment updates at AAN 2026 and discuss how these findings may shape the future of neurologic care At American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, April 18–22, 2026, major ...
Emerging data from AAN 2026 across neuroimmunology, epilepsy, neuromuscular disease, movement disorders and neuroinfectious disease highlighted the continued evolution of neurology toward more precise, personalized and mechanism-driven care. The American Academy of Neurology (AAN) Annual Meeting, Chicago, IL, USA, from April 18–22, 2026, ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
Six key oral presentations from this year’s ADI meeting on diagnosis, therapies and innovation in care Conference coverage | Held from 14–16 April, the 37th Global Conference of Alzheimer’s Disease International (ADI), Lyon, France, brought together global expertise and lived ...
New Phase 2b data highlight the potential of targeting synaptic dysfunction to slow disease progression in dementia with Lewy bodies Dementia with Lewy bodies (DLB) remains an area of high unmet need, with no approved disease-modifying therapies and significant clinical ...
The Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) 2026, held in Copenhagen, Denmark, brought together over 5,800 delegates to discuss advances across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders. ...
We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
In this year-end review, we are pleased to share personal highlights from members of the touchNEUROLOGY Editorial Board, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
In this episode, Nicky speaks with Prof. Georgina Ellison-Hughes from King’s College London about the groundbreaking field of senolytics and their potential to advance the treatment of age-related diseases. From understanding the science behind cellular senescence to how senolytic drugs work and what early clinical trials reveal, this episode explores an exciting frontier in longevity medicine.
In our inaugural touchNEUROLOGY Future Leaders 2025 campaign, we celebrate the next generation of neurologists, rising stars shaping the future of clinical practice, research, and education across neurological specialties.
At AAIC 2025, the Alzheimer’s Association released its first-ever clinical practice guideline (CPG) for blood-based biomarker (BBM) testing in Alzheimer’s disease. This marks a significant step forward in the use of minimally invasive tests to support earlier and more ...
Dr Ellis van Etten, vascular neurologist and clinical scientist at Leiden University Medical Center, specializes in cerebral amyloid angiopathy and other types of cerebral small vessel disease. With early research training at J. Philip Kistler Stroke Research Center at Massachusetts General Hospital, and a PhD on cerebral amyloid angiopathy at Leiden University, she is now actively contributing to international research, including participation in a multicentre phase II trial.
Recent advances in the understanding of agitation in Alzheimer's have informed the development of targeted therapies. In this expert interview, Dr George Grossberg (Saint Louis University School of Medicine, St Louis, MO, USA), an authority in geriatric psychiatry, shares his perspective on the pathophysiological underpinnings of agitation in Alzheimer’s disease, current and emerging pharmacological approaches, and the implications of findings presented at the Alzheimer’s Association International Conference (AAIC) 2025.
With the increasing approval of Alzheimer's disease-modifying therapies and the emergence of more accessible diagnostic tools, the treatment landscape in Alzheimer’s disease (AD) is undergoing a transformation. At AAIC 2025, several pivotal studies and technological innovations were showcased that could reshape both the short- and long-term management of AD. In this expert interview, Prof. George Grossberg (Saint Louis University School of Medicine, St Louis, MO, USA) shares his perspective on the most promising agents in development, as well as his reflections on key findings from Alzheimer’s Association International Conference (AAIC) 2025.
In a significant milestone for Alzheimer’s care, the U.S. Food and Drug Administration has approved lecanemab‑irmb, a once-weekly, subcutaneous autoinjector for maintenance treatment in early Alzheimer’s disease, including mild cognitive impairment and mild dementia. This marks the first amyloid‑targeting therapy permitting at-home administration for ongoing care beyond initial intravenous treatment.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
